Trial Profile
Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2018
Price :
$35
*
At a glance
- Drugs CX 1739 (Primary) ; Remifentanil
- Indications Respiratory insufficiency
- Focus Therapeutic Use
- Sponsors RespireRx Pharmaceuticals
- 08 Jan 2018 According to a RespireRx Pharmaceuticals media release, data from this trial will be presented at The Biotech Showcase 2018.
- 08 Sep 2017 According to a RespireRx Pharmaceuticals media release, results from this trial will be presented at the 2017 Rodman & Renshaw Conference.
- 14 Jun 2017 According to a RespireRx Pharmaceuticals media release, results from this trial will be presented at the 2017 Marcum MicroCap Conference 2017.